Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0311277 (
abdominal obesity
)
2,792
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The prevalence of metabolic syndrome (MetS) and
kidney cancer
is increasing, but studies on the effects of MetS and its components on
kidney cancer
development have had ambiguous results. Overall, 7,613,865 patients from the Korean National Health Insurance System were analyzed and followed up until 2017. Patients with 3 of the necessary five components of MetS were diagnosed with MetS. Patients were divided into subgroups according to two consecutive physical examinations conducted every two years. The Cox proportional hazard regression model was used to survey the independent association between MetS and the risk of
kidney cancer
development.
Kidney cancer
risk was significantly higher in patients with MetS, and there was no difference according to sex. The hazards ratio of
kidney cancer
increased with increasing number of MetS components. For patients not diagnosed with MetS but with
abdominal obesity
and hypertension, the likelihood of developing
kidney cancer
was similar to that of patients diagnosed with MetS. Patients with improved MetS within two years had increased risk of
kidney cancer
compared with those without MetS. MetS is an independent risk factor for
kidney cancer
, and the obesity and hypertension components of MetS are also powerful risk factors.
...
PMID:Metabolic Syndrome Resolved within Two Years is Still a Risk Factor for Kidney Cancer. 3146 66